Programed cell death protein 1 (PD-1) is a cell surface receptor. PD-1 and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells overexpress PD-L1 in order to escape from the PD-1/PD-L1 immunosurveillance mechanism.
Human PD-L1 inhibitor II is a peptide-based molecule. It binds to human PD-1 and inhibits PD-1/PD-L1 binding. This peptide, PDL-1 inhibitor I has anchor residues, WDY that influence binding of hPD-L1 to hPD-1. Developing inhibitors specifically blocking the PD-1/PD-L1 pathway has become a popular approach toward cancer treatment.
CAT# | X21206 |
M.W/Mr. | 2219.6 |
Sequence | One Letter Code: FNWDYSLEELREKAKYK Three Letter Code: H-Phe-Asn-Trp-Asp-Tyr-Ser-Leu-Glu-Glu-Leu-Arg-Glu-Lys-Ala-Lys-Tyr-Lys-OH |
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
Nociceptin/orphanin FQ (N/OFQ) modulates various biological functions, including nociception, via selective stim ...
The 70-kDa heat shock protein (HSP70) contains three domains: the ATPase N-domain, which hydrolyses ATP, the sub ...
P11 (HSDVHK) is a novel peptide ligand containing a PDZ-binding motif (Ser-Asp-Val) with high affinity to integr ...
Camstatin is a similar PEP-19 analogue with enhanced calmodulin binding and antagonism. It is a functional 25- ...
Basic information Desmopressin is a synthetic analogue of the antidiuretic hormone vasopressin used in the treatment of centr ...